之前的研究表明，如果PD-L1表达大于50％，患者就可以选择PD-1抑制剂单药治疗，从而免于接受化疗。然而，最新的报道指出，只有当PD-L1表达水平高达80％时，患者才能够单独使用PD-1抑制剂治疗。PD-L1表达高达80%才能免于化疗 这项研究包括了141名非小细胞肺癌患者，平均年龄62.5岁，66%的患者患的是肺腺癌，51.1%...
Vamsidhar Velcheti, et al., Five-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥50% Advanced NSCLC, Clinical Lung Cancer (2024).
Nikolic Nikola , et al., Brief Report: Predictive value of PD-L1 expression in non-small-cell lung can- cer - should we set the bar higher for monotherapy?, Clinical Lung Cancer (2023)
参考文献: Meshulami N, Tavolacci S, de Miguel-Perez D, Rolfo C, Mack PC, Hirsch FR. Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology? Clin Lung Cancer. 2...
欢迎关注癌度,我们陪您走好防癌抗癌的每一步! . 参考文献: Nikolic Nikola , et al., Brief Report: Predictive value of PD-L1 expression in non-small-cell lung can- cer - should we set the bar higher for monotherapy?, Cli...
欢迎关注癌度,我们陪您走好防癌抗癌的每一步! 参考文献: Nikolic Nikola , et al., Brief Report: Predictive value of PD-L1 expression in non-small-cell lung can- cer - should we set the bar higher for monotherapy?, Clinical Lung Cancer (2023)...
欢迎关注癌度,我们陪您走好防癌抗癌的每一步! . 参考文献: Nikolic Nikola , et al., Brief Report: Predictive value of PD-L1 expression in non-small-cell lung can- cer - should we set the bar higher for monotherapy?, Clinical Lung Cancer (2023)...
如果患者能从ALK的各种靶向药物中获益很长,那么他们的预期生存期还是相当长的。 欢迎关注癌度,了解肿瘤诊疗最新治疗知识! 参考文献: Yingying Pan, et al., Association of PD-L1 expression with efficacy of alectinib in advanced NSCLC patients with ALK fusion, Lung Cancer (2023)...
https://u.wechat.com/MFyT_vWQMAlv6-sjlOt1LHs (二维码自动识别) 参考文献: Vamsidhar Velcheti, et al., Five-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥50% Advanced NSCLC, Clinical Lung Cancer (2024)....
Meshulami N, Tavolacci S, de Miguel-Perez D, Rolfo C, Mack PC, Hirsch FR. Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology? Clin Lung Cancer. 2023 Jul;24(5):401-406. doi: 10.1016/j.cllc.2023.03.014. Epub 2023 Apr...